LMT-28 (Cat.No:I014451) is a small molecule inhibitor that targets a specific protein involved in cancer cell growth and survival. It has shown promise as a potential anticancer agent in preclinical studies. LMT-28 acts by interfering with cellular signaling pathways, inhibiting tumor growth, and inducing cancer cell death. Further research is needed to explore its therapeutic potential.
| Catalog Number | I014451 |
| CAS Number | 1239600-18-0 |
| Synonyms | LMT-28; LMT 28; LMT28;;(4S)-3-[(2S,3S)-3-Hydroxy-2-methyl-4-methylene-1-oxononyl]-4-(1-methylethyl)-2-oxazolidiNA |
| Molecular Formula | C17H29NO4 |
| Purity | 95% |
| Solubility | Soluble in DMSO |
| InChI | InChI=1S/C17H29NO4/c1-6-7-8-9-12(4)15(19)13(5)16(20)18-14(11(2)3)10-22-17(18)21/h11,13-15,19H,4,6-10H2,1-3,5H3/t13-,14+,15+/m0/s1 |
| InChIKey | UDXWSYOXIRPYFK-RRFJBIMHSA-N |
| SMILES | O=C1OC[C@H](C(C)C)N1C([C@@H](C)[C@H](O)C(CCCCC)=C)=O |
| Reference | </br>1: Armstead WM, Hekierski H, Pastor P, Yarovoi S, Higazi AA, Cines DB. Release of IL-6 After Stroke Contributes to Impaired Cerebral Autoregulation and Hippocampal Neuronal Necrosis Through NMDA Receptor Activation and Upregulation of ET-1 and JNK. Transl Stroke Res. 2018 Feb 23. doi: 10.1007/s12975-018-0617-z. [Epub ahead of print] PubMed PMID: 29476447.</br> 2: Hong SS, Choi JH, Lee SY, Park YH, Park KY, Lee JY, Kim J, Gajulapati V, Goo JI, Singh S, Lee K, Kim YK, Im SH, Ahn SH, Rose-John S, Heo TH, Choi Y. A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor β Subunit, Glycoprotein 130. J Immunol. 2015 Jul 1;195(1):237-45. doi: 10.4049/jimmunol.1402908. Epub 2015 May 29. PubMed PMID: 26026064.</br></br></br> |
